RGX-202 (800 mg/kg; p.o. for 35 days) reduces UN-KPC-961 pancreatic tumoral creatine levels in B6129SF1/J mice[1]. RGX-202 (approximately 650 mg/kg; i.p. daily for 14 days) treatment reduces Lvm3b cells liver metastatic colonization by eightfold in NOD-SCID mice[1]. Animal Model: UN-KPC-961 pancreatic tumor-bearing B6129SF1/J mice[1] Dosage: 800 mg/kg Administration: p.o. for 35 days Result: Suppressed tumoral d3-creatine import by 50% at 800 mg/kg. Animal Model: 6- to 9-week-old C57BL/6J male wild-type mice[1] Dosage: 100, 250, 500 mg/KG in sterile 0.9% NaCl Administration: p.o. for 35 days Result: Inhibited tissue uptake of d3-creatine in a dose-dependent manner by up to 75% at 500 mg/kg.
In Vitro
RGX-202 (10 μM; 96 hours) reduces cell growth, and reveals a nearly complete depletion of phosphocreatine (>99%), greater than 79% reduction in cellular creatine and a substantial (46%) reduction in intracellular ATP levels relative to control cells in hypoxia[1].
Kinase Assay
Cell Assay
Animal Administration
References
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
